RavenQuest BioMed Inc.
RVVQF · OTC
7/31/2019 | 4/30/2019 | 1/31/2019 | 10/31/2018 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | -$0 |
| % Growth | 8.6% | 117.7% | 312.8% | – |
| Cost of Goods Sold | $0 | $1 | -$0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 62.4% | -20.1% | -55% | 130.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $2 | $2 | $3 |
| SG&A Expenses | $2 | $2 | $2 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | -$2 | -$2 | -$4 |
| Operating Expenses | $0 | -$0 | $1 | -$0 |
| Operating Income | -$3 | -$2 | -$2 | -$11 |
| % Margin | -388.2% | -296.1% | -805.6% | 7,551.8% |
| Other Income/Exp. Net | -$0 | -$1 | -$1 | -$13 |
| Pre-Tax Income | -$3 | -$3 | -$3 | -$23 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$3 | -$3 | -$3 | -$23 |
| % Margin | -440.2% | -490.6% | -1,064.6% | 16,188.7% |
| EPS | -0.026 | -0.028 | -0.028 | -0.21 |
| % Growth | 6.1% | 1.8% | 86.5% | – |
| EPS Diluted | -0.026 | -0.028 | -0.028 | -0.21 |
| Weighted Avg Shares Out | 120 | 115 | 113 | 109 |
| Weighted Avg Shares Out Dil | 120 | 115 | 113 | 109 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $0 | $1 | $2 |
| EBITDA | -$1 | -$2 | -$2 | -$21 |
| % Margin | -200.2% | -299.3% | -548.9% | 14,776.6% |